昭和大学

腫瘍分子生物学研究所

Publications

業績

2014年度

原著論文

Fujita K, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Sasaki Y, Kato Y: Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. Pharm. Res., 31(1), 204-215 (2014). Kaneta T, Fujita K, Akiyama Y, Kawara K, Sunakawa Y, Kawachi A, Shimada K, Sasaki Y: No pharmacokinetic alteration of docetaxel following coadministration of aprepitant 3 h before docetaxel infusion. Cancer Chemother. Pharmacol., 74(3), 539-547 (2014). Ito H, Inoue H, Kimura S, Ohmori T, Ishikawa F, Gohda K, Sato J: Prognostic impact of the number of viable circulating cells with high telomerase activity in gastric cancer patients: a prospective study. Int. J. Oncol., 45(1), 227-234 (2014). Ishida K, Hirose T, Yokouchi J, Oki Y, Kusumoto S, Sugiyama T, Ishida H, Shirai T, Nakashima M, Yamaoka T, Ohnishi T, Ohmori T, Kagami Y: Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer. Mol. Clin. Oncol., 2(3), 405-410 (2014). Chattopadhyay R, Dyukova E, Singh N, Ohba M, Rao G: Vascular endothelial tight junctions and barrier function are disrupted by 15(S)-hydroxyeicosatetraenoic acid partly via protein kinase C ε-mediated zona occludens-1 phosphorylation at threonine 770/772. J. Biol. Chem., 289(6), 3148-3163 (2014). Correspondence Fujita K, Hirose T, Kusumoto S, Sugiyama T, Shirai T, Nakashima M, Akiyama Y, Sasaki Y: High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer. Lung Cancer, 86(1), 113-114 (2014).

総説

藤田健一:腎機能障害患者における肝消失型抗がん薬の特異な体内動態について.ファルマシア「最前線」,50(4), 300-304 (2014).

著書

藤田健一,佐々木康綱:乳がん治療におけるエベロリムその薬理作用・薬物動態 エベロリムスによる乳がん治療の新展開(野口眞三郎),メディカルレビュー社 pp. 58-68 (2014).